AstraZeneca AZN announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recu
https://www.nasdaq.com/articles/astrazeneca-azn-imfinzi-combo-gets-eu-nod-uterine-cancer